3FNC1†Present address: Foreign Animal Disease Division, Animal Disease Control Department, National Veterinary Research and Quarantine Service, 480 Anyang-6 dong, Manan-gu, Anyang 40-824, Republic of Korea.
3FNC2‡Present address: Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-852, Japan.
It is well known that anti-prion protein (PrP) monoclonal antibodies (mAbs) inhibit abnormal isoform PrP (PrPSc) formation in cell culture. Additionally, passive immunization of anti-PrP mAbs protects the animals from prion infection via peripheral challenge when mAbs are administered simultaneously or soon after prion inoculation. Thus, anti-PrP mAbs are candidates for the treatment of prion diseases. However, the effects of mAbs on disease progression in the middle and late stages of the disease remain unclear. This study carried out intraventricular infusion of mAbs into prion-infected mice before and after clinical onset to assess their ability to delay disease progression. A 4-week infusion of anti-PrP mAbs initiated at 120 days post-inoculation (p.i.), which is just after clinical onset, reduced PrPSc levels to 70–80 % of those found in mice treated with a negative-control mAb. Spongiform changes, microglial activation and astrogliosis in the hippocampus and thalamus appeared milder in mice treated with anti-PrP mAbs than in those treated with a negative-control mAb. Treatment with anti-PrP mAb prolonged the survival of mice infected with Chandler or Obihiro strain when infusion was initiated at 60 days p.i., at which point PrPSc is detectable in the brain. In contrast, infusion initiated after clinical onset prolonged the survival time by about 8 % only in mice infected with the Chandler strain. Although the effects on survival varied for different prion strains, the anti-PrP mAb could partly prevent disease progression, even after clinical onset, suggesting immunotherapy as a candidate for treatment of prion diseases.
BateC.,
BoshuizenR. S.,
LangeveldJ. P.,
WilliamsA.2002; Temporal and spatial relationship between the death of PrP-damaged neurones and microglial activation. Neuroreport 13:1695–1700[CrossRef]
ChesebroB.,
RaceR.,
KercherL.2005; Scrapie pathogenesis in brain and retina: effects of prion protein expression in neurons and astrocytes. J Neurovirol 11:476–480[CrossRef]
DemaimayR.,
AdjouK. T.,
BeringueV.,
DemartS.,
LasmézasC. I.,
DeslysJ. P.,
SemanM.,
DormontD.1997; Late treatment with polyene antibiotics can prolong the survival time of scrapie-infected animals. J Virol 71:9685–9689
EhlersB.,
DiringerH.1984; Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol 65:1325–1330[CrossRef]
El KhouryJ.,
ToftM.,
HickmanS. E.,
MeansT. K.,
TeradaK.,
GeulaC.,
LusterA. D.2007; Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13:432–438[CrossRef]
EnariM.,
FlechsigE.,
WeissmannC.2001; Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci U S A 98:9295–9299[CrossRef]
FarquharC. F.,
DickinsonA. G.1986; Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J Gen Virol 67:463–473[CrossRef]
Fernandez-BorgesN.,
BrunA.,
WhittonJ. L.,
ParraB.,
Diaz-San SegundoF.,
SalgueroF. J.,
TorresJ. M.,
RodriguezF.2006; DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge. J Virol 80:9970–9976[CrossRef]
HeppnerF. L.,
MusahlC.,
ArrighiI.,
KleinM. A.,
RülickeT.,
OeschB.,
ZinkernagelR. M.,
KalinkeU.,
AguzziA.2001; Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294:178–182[CrossRef]
HoriuchiM.,
CaugheyB.1999; Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J 18:3193–3203[CrossRef]
HoriuchiM.,
YamazakiN.,
IkedaT.,
IshiguroN.,
ShinagawaM.1995; A cellular form of prion protein (PrPC) exists in many non-neuronal tissues of sheep. J Gen Virol 76:2583–2587[CrossRef]
HoriuchiM.,
MochizukiM.,
IshiguroN.,
NagasawaH.,
ShinagawaM.1997; Epitope mapping of a monoclonal antibody specific to feline panleukopenia virus and mink enteritis virus. J Vet Med Sci 59:133–136[CrossRef]
KanekoK.,
PeretzD.,
PanK. M.,
BlochbergerT. C.,
WilleH.,
GabizonR.,
GriffithO. H.,
CohenF. E.,
BaldwinM. A.,
PrusinerS. B.1995; Prion protein (PrP) synthetic peptides induce cellular PrP to acquire properties of the scrapie isoform. Proc Natl Acad Sci U S A 92:11160–11164[CrossRef]
KimC. L.,
UmetaniA.,
MatsuiT.,
IshiguroN.,
ShinagawaM.,
HoriuchiM.2004a; Antigenic characterization of an abnormal isoform of prion protein using a new diverse panel of monoclonal antibodies. Virology 320:40–51[CrossRef]
KociskoD. A.,
CaugheyW. S.,
RaceR. E.,
RoperG.,
CaugheyB.,
MorreyJ. D.2006; A porphyrin increases survival time of mice after intracerebral prion infection. Antimicrob Agents Chemother 50:759–761[CrossRef]
KuwataK.,
NishidaN.,
MatsumotoT.,
KamatariY. O.,
Hosokawa-MutoJ.,
KodamaK.,
NakamuraH. K.,
KimuraK.,
KawasakiM.other authors2007; Hot spots in prion protein for pathogenic conversion. Proc Natl Acad Sci U S A 104:11921–11926[CrossRef]
MorrisseyM. P.,
ShakhnovichE. I.1999; Evidence for the role of PrPC helix 1 in the hydrophilic seeding of prion aggregates. Proc Natl Acad Sci U S A 96:11293–11298[CrossRef]
NicollJ. A.,
WilkinsonD.,
HolmesC.,
SteartP.,
MarkhamH.,
WellerR. O.2003; Neuropathology of human Alzheimer disease after immunization with amyloid- β peptide: a case report. Nat Med 9:448–452[CrossRef]
OrgogozoJ. M.,
GilmanS.,
DartiguesJ. F.,
LaurentB.,
PuelM.,
KirbyL. C.,
JouannyP.,
DuboisB.,
EisnerL.other authors2003; Subacute meningoencephalitis in a subset of patients with AD after A β 42 immunization. Neurology 61:46–54[CrossRef]
RainovN. G.,
TsuboiY.,
Krolak-SalmonP.,
VighettoA.,
Doh-UraK.2007; Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate?. Expert Opin Biol Ther 7:713–726[CrossRef]
SchwarzA.,
KrätkeO.,
BurwinkelM.,
RiemerC.,
SchultzJ.,
HenkleinP.,
BammeT.,
BaierM.2003; Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci Lett 350:187–189[CrossRef]
SigurdssonE. M.,
BrownD. R.,
DanielsM.,
KascsakR. J.,
KascsakR.,
CarpR.,
MeekerH. C.,
FrangioneB.,
WisniewskiT.2002; Immunization delays the onset of prion disease in mice. Am J Pathol 161:13–17[CrossRef]
SpeareJ. O.,
RushT. S.III,
BloomM. E.,
CaugheyB.2003; The role of helix 1 aspartates and salt bridges in the stability and conversion of prion protein. J Biol Chem 278:12522–12529[CrossRef]
WhiteA. R.,
EneverP.,
TayebiM.,
MushensR.,
LinehanJ.,
BrandnerS.,
AnsteeD.,
CollingeJ.,
HawkeS.2003; Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422:80–83[CrossRef]